sitagliptin-phosphate and Pemphigus

sitagliptin-phosphate has been researched along with Pemphigus* in 2 studies

Other Studies

2 other study(ies) available for sitagliptin-phosphate and Pemphigus

Article	Year
Decrease of Anti-DSG3, but Not Anti-DSG1 Antibody, After Cessation of Sitagliptin Treatment in a Patient With Pemphigus Vulgaris. JAMA dermatology, 2019, Mar-01, Volume: 155, Issue:3 Topics: Autoantibodies; Desmoglein 1; Desmoglein 3; Diabetes Mellitus, Type 2; Drug Eruptions; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Monitoring, Physiologic; Pemphigus; Recurrence; Risk Assessment; Sitagliptin Phosphate; Time Factors; Withholding Treatment	2019
Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: A case report. The Journal of dermatology, 2018, Volume: 45, Issue:2 Topics: Biopsy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Pemphigus; Sitagliptin Phosphate; Skin	2018

Article

Year

Decrease of Anti-DSG3, but Not Anti-DSG1 Antibody, After Cessation of Sitagliptin Treatment in a Patient With Pemphigus Vulgaris.

JAMA dermatology, 2019, Mar-01, Volume: 155, Issue:3

Topics: Autoantibodies; Desmoglein 1; Desmoglein 3; Diabetes Mellitus, Type 2; Drug Eruptions; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Monitoring, Physiologic; Pemphigus; Recurrence; Risk Assessment; Sitagliptin Phosphate; Time Factors; Withholding Treatment

2019

Pemphigus vulgaris developing after 6-month treatment with a dipeptidyl peptidase-4 inhibitor: A case report.

The Journal of dermatology, 2018, Volume: 45, Issue:2

Topics: Biopsy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Male; Middle Aged; Pemphigus; Sitagliptin Phosphate; Skin

2018